首页> 外文期刊>The pharmaceutical journal >Palliative management in end-stage liver disease
【24h】

Palliative management in end-stage liver disease

机译:末期肝病中的姑息治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Liver disease has become a growing health burden on the NHS, mostly owing to an increase in alcohol consumption, viral hepatitis and obesity. Liver disease is the third major cause of premature death in the UK; however, the management of patients who are at the advanced (cirrhotic) stage of liver disease remains poor, with only 16% of patients having clear discussions about their preferred place of death and 83% of patients dying in hospital. This is in part owing to the unpredictable nature of liver disease, precluding early referral for palliative care input. The number of patients with liver disease is expected to increase over the next few years, presenting a challenge for healthcare professionals.
机译:肝病已成为NHS的生命负担,主要是由于酒精消耗,病毒性肝炎和肥胖增加。 肝病是英国过早死亡的第三个主要原因; 然而,处于肝病先进(Cirrhotic)阶段的患者的管理仍然是穷人,只有16%的患者有关他们首选的死亡地点和83%的患者在医院死亡的患者。 这部分是由于肝病的不可预测性质,妨碍早期推荐进行姑息治疗。 肝病患者的数量预计将在未来几年增加,为医疗保健专业人员提出挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号